Review

Therapeutic Targets in Amyotrophic Lateral Sclerosis: Focus on Ion Channels and Skeletal Muscle

Nancy Tarantino, Ileana Canfora, Giulia Maria Camerino and Sabata Pierno *

Department of Pharmacy-Drug Sciences, University of Bari Aldo Moro, 70125 Bari, Italy; nancy.tarantino@uniba.it (N.T.); ileana.canfora@uniba.it (I.C.); giuliamaria.camerino@uniba.it (G.M.C.)
* Correspondence: sabata.pierno@uniba.it

Abstract: Amyotrophic Lateral Sclerosis is a neurodegenerative disease caused by progressive loss of motor neurons, which severely compromises skeletal muscle function. Evidence shows that muscle may act as a molecular powerhouse, whose final signals generate in patients a progressive loss of voluntary muscle function and weakness leading to paralysis. This pathology is the result of a complex cascade of events that involves a crosstalk among motor neurons, glia, and muscles, and evolves through the action of converging toxic mechanisms. In fact, mitochondrial dysfunction, which leads to oxidative stress, is one of the mechanisms causing cell death. It is a common denominator for the two existing forms of the disease: sporadic and familial. Other factors include excitotoxicity, inflammation, and protein aggregation. Currently, there are limited cures. The only approved drug for therapy is riluzole, that modestly prolongs survival, with edaravone now waiting for new clinical trial aimed to clarify its efficacy. Thus, there is a need of effective treatments to reverse the damage in this devastating pathology. Many drugs have been already tested in clinical trials and are currently under investigation. This review summarizes the already tested drugs aimed at restoring muscle-nerve cross-talk and on new treatment options targeting this tissue.

Keywords: amyotrophic lateral sclerosis; skeletal muscle; ion channels; animal models; clinical trials; therapy

1. Introduction

Amyotrophic Lateral Sclerosis (ALS) is a progressive neurodegenerative disease. It is characterized by selective degeneration of upper and lower motor neurons (MN), which causes weakness, muscle wasting, and fasciculation. These symptoms suggest a strong involvement of skeletal muscle in the pathology. Among the causes of MN degeneration, the glutamate induced excitotoxicity plays a major role [1]. It was also shown that glial cell dysfunction contributes to the disease [2]. At the NMJ, alterations in perisynaptic Schwann cell (PSC), the glial cells placed at this synapse, can influence their ability to regulate NMJ stability, impairing compensatory reinnervation in ALS. In addition, PSC alteration compromises the supply of several trophic molecules important for muscle-nerve communication.

Affected individuals suffer from progressive paralysis and can die within 3 to 5 years after the onset of symptoms due to respiratory failure. ALS is sporadic (sALS) in about 90% of cases, and the remaining 10% are of genetic (fALS) origin, with a large subgroup carrying mutations in the superoxide dismutase enzyme (SOD1), a cell scavenger of superoxide anion symptoms [3]. Other mutations in several genes, such as ANG (angiogenin), DCTN1 (dynactin), TDP43 (TAR DNA-binding protein 43), FUS (protein Fused in Sarcoma), and C9orf72 (chromosome 9 open reading frame 72) were linked to familial forms of ALS [4]. In the last years, several animal models were generated by reproducing various mutations, with the aim of studying this pathology and the involvement of various tissues [5]. Actually, clinical symptoms and the pathogenic mechanisms were found to be the same in sporadic and familial cases of ALS.
Despite the fact that it was clinically described many years ago, the mechanisms underlying ALS pathogenesis are not yet fully understood. Studies in the animal models of ALS and in the patients reveal a plethora of alterations, such as an increase of glutamate-mediated excitotoxicity, oxidative stress, defective axonal transport, a dysregulation in autophagy and ubiquitin proteasome system, protein-misfolding events, mitochondrial impairment, and alteration of immune responses [6]. Thus, with the aim to better investigate the etiopathogenesis of the disease, the preclinical analysis of transgenic mouse models can be helpful and very important not only for studying the mechanisms leading to the tissue damage, but also to test new effective drugs to submit to clinical trials. The SOD1-G93A transgenic mouse model is the most studied because it recapitulates several aspects of the disease allowing the drafting of a clear hypothesis [6–8]. The genetic mutation is ubiquitously expressed and is linked to a toxic gain of function of the SOD1 enzyme, with the generation of free radicals that leads to cell injury and death. Additionally, the mutation induces conformational instability and misfolding of SOD1 protein, resulting in the formation of intracellular aggregates that inhibit normal proteasomal function, disrupting axonal transport and vital cellular functions. Additionally, the mutation in the transactive response DNA-binding protein43 (TARDBP gene, TDP43 protein) is a common cause of ALS [4,9,10]. To date, more than 40 TARDBP mutations are associated with the ALS phenotype. TDP43 was identified as a key component of the insoluble and ubiquitinated inclusions in the brain of ALS patients. Full length, wild type TDP43 is found to be aggregated in the vast majority of sALS and fALS patients. Studies in vivo and in vitro demonstrate that this protein is not particularly prone to aggregation by itself, unless it is highly overexpressed. Protein aggregates may arise as a consequence of improper folding of a mutant protein, but also following oxidative modifications of crucial proteins, defective chaperons, and protein degradation.

At present, there are neither clear biomarkers nor resolutive therapies or disease-modifying treatments for ALS. The only approved treatment option is riluzole, which is able to reduce the glutamate-induced excitotoxicity [11]. However, riluzole increases survival of patients by only a few months [12]. Thus, it is possible that different drugs acting at various levels and on various tissues may be useful in solving this multifactorial disease. Indeed, recently, the antioxidant edaravone was introduced in therapy because of its role as a disease-modifying agent [13]. Unfortunately, it was rapidly withdrawn from the European market and waiting for further efficacy studies.

2. Pathological Features and Skeletal Muscle Involvement

Skeletal muscle is now considered as an important target tissue involved in the pathogenesis of ALS, through activation of a retrograde signaling cascade that degrades affected motor neurons [14,15]. Skeletal muscle function is regulated by numerous factors, including satellite cells, cell metabolism, mitochondrial activity, and RNA processing. In ALS, these factors show various levels of dysregulation within skeletal muscle. Disease onset is accompanied with cramping and twitching, spasticity, severe muscle weakness, and atrophy in limbs and trunk. The pathology progresses to paralysis of voluntary muscles, including diaphragm. Muscle atrophy has been observed in both the classical mouse model SOD1-G93A and in the transgenic mouse model, in which the mutant SOD1 is expressed only in skeletal muscle (MLC/SOD1-G93A) and not in the neurons [16]. These mice also show reduced tetanic and specific force as well as NMJ abnormalities. This model was demonstrated to be useful in studying the involvement of skeletal muscle in the pathology. The appearance of early events before denervation were described in skeletal muscle of these animals (MLC/SOD), supporting the “dying back” hypothesis.

In this context, we investigated sarcolemma ion channels that play a crucial role in muscle function and are important to maintaining NMJ stability. Resting chloride conductance (gCl), sustained by the muscle CIC-1 channel, controls sarcolemma excitability [17,18]. Indeed, a reduction of CIC-1 channel activity and resting gCl generates myotonic-like symptoms [19–21]. Skeletal muscle potassium channels are important for skeletal muscle
function since they are involved in cell excitability and metabolism. Interestingly, we found that macroscopic resting gCl was strongly reduced in SOD1-G93A mice as compared to wild-type (WT), and potassium conductance (gK) was significantly increased. In accord, patch clamp studies showed different activity of the Kir channels and an altered sensitivity to ATP. Consequently, sarcolemma excitability was increased. Additionally, in MLC/SOD1-G93A mice, we found a reduction of gCl which was restored by the in vitro application of chelerythrine, an inhibitor of protein kinase C (PKC), suggesting its involvement in the reduction of gCl [22]. Indeed, it is known that PKC is a regulatory protein of the ClC-1 activity, since it phosphorylates and closes the channel [23,24].

A multivariate statistical analysis of PCR data, using machine learning algorithms, identified some discriminant genes in these mice. Surprisingly, a modification of the expression of different ion channels in skeletal muscle was found. In particular, the expression of ClC-1, which is known to be the major chloride channel expressed in skeletal muscle, was reduced. This was accompanied by the increased expression of PKC, also involved in NMJ disruption [25,26]. We also showed that the expression of other genes were reduced in skeletal muscle, such as irisin, a pro-myogenic factor able to contrast denervation [27]. All these data demonstrate the involvement of skeletal muscle in the pathology.

Additional support to the important role of skeletal muscle was provided by the observation that the postnatal development in the absence of skeletal muscle results in the sequential ablation of motor neurons from the spinal cord to the brain [28], demonstrating that the nervous tissue development is coupled to skeletal myogenesis. Moreover, the expression of mutant SOD1 in motor neurons alone is not sufficient to cause ALS-like symptoms in mice [29–31]. Based on these results, it cannot be excluded that skeletal muscle is involved in ALS etiopathogenesis at the same time. Thus, skeletal muscle can be an attractive target of therapy, because drug specifically affecting skeletal muscle can be useful to ameliorate NMJ and MN function and can be used together with current therapies (Figure 1).

**Figure 1.** Scheme of the pathological events involving new biomarkers of ALS. Skeletal muscle is partially responsible for the MN decline and is in turn affected by denervation. The production of myokines is severely impaired in skeletal muscle with alteration of NMJ integrity and axonal growth. In addition, the increased expression of Protein kinase C can be responsible for the loss of synapses at NMJ and impairment of skeletal muscle excitability and function (see text for details).

### 3. Current Clinical Trials by Using Drugs Targeting Skeletal Muscle

To date, riluzole is the only available drug for ALS therapy from 1995. This drug is neuroprotective, reducing the excitotoxic effect of excessive glutamate [32] and inhibiting voltage-dependent sodium channels [33,34]. Recently, the free radical scavenger, edaravone,
was evaluated in a phase 3 randomized study and then introduced in therapy, but rapidly withdrawn in Europe and waiting for further efficacy studies. Indeed, this trial needs to be re-evaluated because of the small study size, the short study duration, and the lack of proven data on survival [35]. Yet, the anti-inflammatory and neuroprotective tyrosine kinase inhibitor, masitinib, showed new possibilities for cure [36]. Indeed, in a randomized controlled trial, when added to riluzole, it showed slight positive effects to be further evaluated.

During the last 10 years, the number of clinical studies focusing on ALS has grown exponentially. Potential therapeutic agents with different mechanisms of action have been tested with the aim to target one or more of the pathological aspects of this multifactorial disease (i.e., oxidative stress, inflammation, mitochondria, and neurotrophic factors deficit). Unfortunately, many of the tested compounds failed to induce some benefits on disease progression or survival. It is important to underline that there are many potential reasons for this failure. Indeed, clinical trial design is complicated by the low number of patients, different ALS patient subpopulations, late stage of initiation of clinical trial, and difficulty in the achievement of clinically relevant primary outcome measures. Moreover, the heterogeneity of the pathogenic mechanisms and the involvement of different tissues requires pharmacological multi-target strategies. For these reasons, it can be useful to search for more relevant outcome measures and new biomarkers of disease progression for trial design. In this context, skeletal muscle can be analyzed as an important drug target. Indeed, different studies show that the restoration of skeletal muscle function can have a possible neuroprotective role in this pathology, a phenomenon called saving-back [22,37]. Thus, drugs targeting skeletal muscle can also be useful for preserving NMJ integrity and delaying MN impairment. Here, we analyzed the past and current clinical trials aimed at targeting skeletal muscle and NMJ as useful therapeutic opportunities (ClinicalTrials.gov, accessed on 17 January 2022).

Pharmacological interventions often alleviate symptoms. As shown in Table 1, different drugs are categorized in a class of compounds able to affect the various pathological aspects. Drugs described to relieve spasticity and muscle cramps are baclofen, cannabinoids, botulin toxin, carbamazepine, or mexiletine, as well as magnesium supplements. Mitochondrial abnormalities described in skeletal muscle from ALS patients have been detected frequently in aggregates adjacent to the sarcolemma [38]. Accumulation of reactive oxygen species (ROS) were observed in skeletal muscle of ALS patients and SOD1-G93A mice [39]. These mice also showed an increase in cyclophilin D expression, which promotes the opening of the mitochondrial permeability transition pore (mPTP), increasing mitochondria membrane depolarization and further generation of ROS [39,40]. Indeed, the genetic deletion of cyclophilin D may delay disease onset and extend survival. Therefore, different drugs have been tested in clinical trials that aimed to ameliorate mitochondrial function and ATP production (Table 1). In particular, olesoxime, a cholesterol like compound that was already proposed for other invalidating pathologies, such as SMA [41]; and dexpramipexole, with neuroprotective properties by direct effects on mitochondria and stabilization of the proton gradients needed for ATP production [42]. Among antioxidant compounds, as an alternative to edaravone, creatine supplementation was tested in clinical trial without clear benefits [43]. Autophagy stimulators were tested, with the aim to recycle damaged cytoplasmic constituents and protein aggregates in skeletal muscle of ALS patients [44]. However, some authors claim that a great inhibition of mTOR can be detrimental in ALS condition, due to possible accumulation of cytoplasmic autophagosomes. In contrast, other authors describe a slight amelioration of symptoms [45]. To clarify this discrepancy, new clinical trials are ongoing [46]. The supplementation of trophic factors, such insulin-like growth factor 1 (IGF1) and growth hormone (GH), are able to stimulate growth and development of myogenesis through increase of protein synthesis. The up-regulation of IGF1 in muscle can improve hindlimb muscle strength and motor neuron survival. It was described that muscle-restricted expression of insulin-like growth factor type 1 (IGF-1) isoform maintained muscle integrity and enhanced satellite cell activity in SOD1-G93A transgenic mice, inducing calcineurin-mediated regenerative pathways [14,47].
However, in a clinical trial, subcutaneous recombinant human IGF1 administration did not
corroborate these results, failing to detect changes in muscle strength or function [48,49].
Additionally, GH was ineffective. Recently, a new combination of two small molecules,
sodium phenylbutyrate and tauroursodeoxycholic acid (TUDCA), seems to be promising
in the restoration of muscle and neuronal function and increasing survival in ALS patients.
These drugs show antioxidant, antiapoptotic, and neuroprotective effects in preclinical
studies. Sodium phenylbutyrate helps proteins maintain their normal conformation, pre-
venting aggregation. TUDCA improves mitochondrial energy production and endoplasmic
reticulum normal function in cells [50]. Among drugs acting on skeletal muscle proteins,
reldesemtiv is a fast skeletal muscle troponin activator. It is a small molecule designed
to slow the release of calcium, improving muscle function and movement. This drug is
more potent than other skeletal muscle activators, such as tirasemtiv, with the advantage of
lower doses. Additionally, because reldesemtiv does not cross the blood-brain barrier, it
should cause fewer significant side effects than tirasemtiv. Additionally, levosimendan, by
sensitizing the skeletal muscle to calcium signaling, helps it to contract more easily. Skeletal
muscle defect in ALS involves acetylcholine receptors (AChRs). Thus, endocannabinoid
palmitoylethanolamide (PEA) can promote AChRs currents in ALS muscle [51]. Addition-
ally, pimozide was tested in a clinical study based on its ability to inhibit the T-type Ca2+
channel and to promote beneficial effects at neuromuscular junctions (NMJs) transmission.
In the past, it was shown to be unable to induce significant results [52]. However, new
clinical trials are recruiting, based on positive preclinical and pilot studies showing an
effect at doses lower than that used for other therapeutic indications [53]. Moreover, new
pimozide derivatives are currently studied as promising drugs [54]. Old clinical studies
have evaluated sport therapy as a possible beneficial measure. Physical therapy is sup-
posed to improve the overall quality of life in patients with ALS. However, the studies
that have been conducted to date were too small to determine the benefits of exercises
for ALS patients. This therapy can help to reduce the frequency and intensity of muscle
cramps, and to prevent pain and stiffness. Studies using ALS animal models have shown
that the animals benefit from moderate exercise, but intense exercise causes an acceleration
of weakness [55].

It should be underlined that other new clinical trials are based on genetic approaches.
Antisense oligonucleotides (ASOs) are current drugs in development for the different genetic
forms of the disease. ASO are short single stranded nucleotide sequences that bind mRNA
to modulate gene expression. Although promising in preclinical models of ALS caused
by SOD1 mutations and C9orf72 repeat expansions [56–59], they need long-time studies
and elevated number of patients. It should be considered that these therapies often require
administration by invasive routes (i.e., intrathecal or intracerebral) to reach the central nervous
system (CNS) since they are unable to cross the blood-brain barrier (BBB) and can develop
cytotoxicity. Moreover, these therapies are limited in the sporadic forms that represent the
major percent of ALS forms. Recently, encouraging results have been reached using tofersen
during phase 2 clinical trial in ALS patients with SOD1 mutation [60]. By reducing mutated
SOD1 level, the drug showed to increase muscle force. Thus, despite the risk, antisense
technology merits further investigation. Additionally, pyrimethamine was found to produce
a significant reduction in total CSF SOD1 protein content in patients with ALS caused by
different SOD1 mutations. Although the mechanism was not clear, pyrimethamine was found
to be safe and well tolerated in ALS patients [61]. Further long-term studies are warranted
to assess clinical efficacy. Moreover, clinical trials using stem cells are ongoing, although the
effects on disease progression are not yet documented. For instance, stem cells programmed
to secrete neurotrophic factors (NTFs) were planned to promote growth and survival of
muscle and nerve cells [62]. Particular attention should be also taken with new technologies
using synthetic microRNA anti-SOD1 (by adeno-associated virus), which are able to target
degrad SOD1 messenger RNA, thereby suppressing the expression of the gene in the
spinal cord and slowing the progression of the disease. Several preclinical [63,64] and clinical
studies [65] have shown the first positive results.
As known, alterations in multiple cell types act synergistically to exacerbate the disease [3], thus, it can be useful to control different pathways when possible.

**Table 1.** Drugs are grouped based on their ability to affect pathogenic mechanism involved in the modification of skeletal muscle function and motor neuron health.

| Class of Drug                  | Drug/Agent                        | Mechanism of Action                                                                 | Trial Number                                      | Bibliography |
|-------------------------------|-----------------------------------|--------------------------------------------------------------------------------------|--------------------------------------------------|--------------|
| Mitochondria protectants      | Olesoxime                         | mitochondrial permeability and transition pore modulation                            | NCT01285583/ NCT00686166 (phase 3)              | [66]         |
|                               | Dexpramipexole                    | mitochondrial function enhancement                                                  | NCT01281189 (phase 3)                            | [42]         |
|                               | Coenzyme Q10                      | mitochondrial cofactor                                                              | NCT00243932                                      | [67]         |
|                               | Tamoxifen                         | protease and autophagy enhancement                                                  | NCT02166944 (phase 2)                            |              |
|                               | Creatine                          | energy production stimulation and oxidative stress response activation               | NCT0070993 (phase 2)                             | [43]         |
| Muscle metabolism protectants | TUDCA + Sodium phenyl butyrate    | skeletal muscle and nervous tissue protection                                       | NCT03127514 (phase 3)                            | [50]         |
|                               | IGF-1                             | anabolic pathways stimulation                                                       | NCT00035815 (phase 3)                            | [49]         |
|                               | GH                                | anabolic pathways stimulation                                                       | NCT0063960 (phase 3)                             | [68]         |
| Fast skeletal muscle troponin activator | Tirasemtiv                      | contraction stimulation                                                              | NCT02496767 (phase 3)                            | [69]         |
|                               | Reldesemtiv                       | contraction stimulation                                                              | NCT03160898 (phase 2)                            | [70]         |
| Modulators of ion channels and excitability | Ezogabine/Retigabine             | K+ channels activation, hyperexcitability inhibition                                 | NCT02450552 (phase 2)                            | [71]         |
|                               | Mexiletine                        | Na+ channel inhibition                                                              | NCT01811355 (phase 4)                            | [72]         |
|                               | Dronabinol                        | TRP channels modulation and cramps relieve                                           | NCT00812851 (not applicable)                      |              |
|                               | Levosimendan                      | Ca++ sensitization K+ opening                                                        | NCT03505021 (phase 3)                            | [73]         |
| Modulators of NMJ function    | Endocannabinoid palmitoyl-ethanolamide (PEA) | stimulation of AChR expression and activity                                      | NCT02645461 (not applicable)                      | [51]         |
|                               | Pimozide                          | NMJ stabilization                                                                   | NCT03272503                                       | [52,53]      |
| Muscle proteostasis           | Rapamycin                         | stimulation of proteins degradation                                                 | NCT03359538 (phase 2)                            | [46]         |
|                               | Colchicine                        | autophagy activation                                                                | NCT03693781 (phase 2)                            | [74]         |
| Other mechanisms              | 1-(beta-D-Ribofuranosyl) nicotinamide chloride and 3,5-Dimethoxy-4'-hydroxy-trans-stilbene | NAD+ level increase and support of sirtuin activity                                 | NCT03489200 (not applicable)                      | [75]         |
|                               | Clenbuterol                       | motor function improvement                                                          | NCT0425709 (phase 2)                             |              |
|                               | Ozanezumab                        | monoclonal antibody that targets neurite outgrowth inhibitor                        | NCT01753076 (phase2)                              | [76]         |
|                               | Acthar gel                        | stimulation of steroids production and regulation of inflammation in skeletal muscle | NCT03068754                                      | [77]         |
| Sport therapy                |                                   | muscle metabolism                                                                   | NCT02548663                                      | [78,79]      |

TRP: Transient Receptor Potential channels; AChR: Acetylcholine Receptor.
4. Preclinical Studies and Proposed Drugs Able to Restore Skeletal Muscle Function

The development of novel therapeutic strategies targeting the skeletal muscle were planned to slow down the onset and progression of this disease [80] based on significant preclinical studies. Here, we report some examples of drugs preclinically tested to restore skeletal muscle function in ALS animal models and were also useful for improving MN performance (Table 2).

Different preclinical studies were performed in consideration of the modifications of trophic factors. For instance, it was found that glial cell-derived neurotrophic factor (GDNF) increased survival through a beneficial effect on the NMJ, since it ameliorates the nerve sprouting ability [81] and MN survival [82]. Since vascular endothelial growth factor (VEGF) promotes angiogenesis and neuronal survival [83], the VEGF supplementation in skeletal muscle of SOD1-G93A mice had positive effects on ALS symptoms [84]. Additionally, neuregulin 1 (NRG1), by activating cell survival pathways, protects NMJ and acetylcholine receptors from decline in SOD1-G93A mice [85]. In line with NMJs preservation, treated mice had better neuromuscular and motor functions [86]. Insulin-like growth factor 1 (IGF-1) is an anabolic compound that promotes satellite cell proliferation and muscle hypertrophy [4]. Muscle-directed gene therapy of IGF-1 in ALS models promotes survival in SOD1-G93A mice and ameliorates MN function [14,87]. Additionally, creatine is an important amino acid of skeletal muscle, proposed in preclinical and clinical studies to compensate energy depletion. This is correlated with a slower progression of the disease in ALS mouse models. Indeed, creatine supplementation ameliorated motor performance and extended survival in SOD1-G93A mice, protected neurons, and reduced the extent of oxidative damage. Due to these observations, supplementation of creatine was evaluated in two clinical trials, unfortunately without significant effects [88]. The anabolic-androgenic steroid (AAS) nandrolone protects mitochondria, reduces muscle atrophy, and supports diaphragm muscle function but does not prevent muscle denervation [89]. Additionally, the AMP-activated protein kinase (AMPK) had a beneficial role in skeletal muscle; indeed, the removal of AMPK from wild-type mice promotes modification of function, as observed in SOD1 mice [90]. AMPK acts as an energy sensor, activating both fatty acid oxidation and mitochondria biogenesis, but also glycolysis [91]. Therefore, detrimental effects of AMPK reduction in ALS are likely to reflect accelerated hypermetabolism and energy deficit through inhibition of both catabolic pathways. In accord, we found a significant decrease in SOD1-G93A mice with respect to WT. Thus, AMPK activation can be of support. In this regard, metformin, a AMPK activator, was tested in a genetic model of the disease and found to be beneficial, improving neurologic phenotype in C9orf72 transgenic mice [92,93].

Recent findings have proposed a beneficial role of trimetazidine in preclinical studies in SOD1-G93A mice [94]. This is a metabolic modulator that inhibits the long-chain mitochondrial 3-ketoacyl coenzyme A thiolase (ACAA2), an enzyme responsible for the oxidation of long-chain fatty acids [95]. It was found to inhibit β-oxidation and fatty acid uptake, improving glucose metabolism [96]. Additionally, it increases mitochondrial protein levels and energy metabolism, and stimulates myogenesis, muscle strength, and oxidative metabolism in muscles, improving NMJ and neuromuscular communication [97]. Those effects extend survival of SOD1-G93A mice. Additionally, ranolazine, an FDA-approved inhibitor of fatty acid β-oxidation, favors the glycolytic process and led to an increase of ATP level in SOD1-G93A mice, and this effect correlates with a temporary recovery of the pathological phenotype [98]. Recently, niclosamide was proposed to be useful in preclinical trials. This drug interferes with different markers of the disease, such as mTOR, STAT3, and NF-kB. Thus, it reduces inflammation and aggregates formation in skeletal muscle, and displays beneficial effects also on muscle atrophy, by promoting regeneration [99]. It has been found that mutations of SOD1 induce upregulation of c-Abl, an apoptosis-related gene, and a decrease of cell viability. The expression of c-Abl was found to be increased in spinal cord from sporadic ALS patients [100]. Thus, the administration of dasatinib [101], a c-Abl inhibitor, was able to inactivate caspase-3, to inhibit cytotoxicity, and to improve innervation at NMJ and survival of SOD1-G93A mice [100].
Many studies have focused on the alterations of neuronal and muscular excitability due to abnormalities in axonal sodium (Na$^+$) and potassium (K$^+$) conductance [102]. It is widely acknowledged that excitotoxicity importantly contributes to ALS by promoting a neurodegenerative cascade via Ca$^{2+}$-mediated processes [103]. Accordingly, the voltage-sensitive Na$^+$ channel blockers, such as mexiletine, have been tested to reduce hyperexcitability, promote membrane stabilization, and control ALS symptoms [72]. Mexiletine was tested in spinal cord cultured cells exposed to a medium derived from astrocytes expressing mutant SOD1-G93A and was found to reduce hyperexcitability, restore basal calcium transients, and prevent motoneuron death [104]. Thus, mexiletine was tested in clinical trials for muscle cramps. Additionally, retigabine, a K$^+$ channels activator indicated as anti-convulsant, was proposed as a regulator of excitability, as well as in the reduction of reactive oxygen species generation [105]. In this regard, it is important to underline that riluzole, the most effective drug used in ALS, acts by inhibiting excitability. This demonstrates the need to improve this pathological aspect.

Our preclinical studies on MLC/SOD1-G93A animals reveal an important role of acetazolamide. Acetazolamide, a carbonic anhydrase inhibitor indicated for excitability disorders, when applied in-vitro, restored the CIC-1 chloride channel activity and sarclemma hyperexcitability in MLC/SOD1-G93A mice [22]. Acetazolamide was already found to beneficially improve CIC-1 function in myotonia congenita through voltage-dependent regulation of the channel [19,106–108]. In support of the need to maintain chloride channel function, the application of chelerythrine, a PKC blocker was found to ameliorate the resting chloride conductance (gCl) in ALS mice, suggesting an important role of PKC-theta in the pathology [25,26,109,110].

Importantly, the benefit of physical activity (mild to moderate) on motor neuron loss and muscle atrophy has been documented in ALS [111,112]. Thus, it could be considered as a possible therapeutic intervention to delay muscle degeneration and to preserve NMJ integrity. Indeed, physical activity can promote myofiber regeneration by activating satellite cells. As a result, an improvement of metabolism and mitochondrial biogenesis can be possible in skeletal muscle [113]. An antioxidant effect and amelioration of GLUT4 glucose transporter expression was also demonstrated. Different studies on animal models have showed that exercises had beneficial effects in neurodegenerative diseases. For instance, swim training affects Akt signaling and ameliorates loss of skeletal muscle mass in a mouse model of ALS [114]. Moreover, myokines produced by skeletal muscle during exercise (i.e., BDNF and irisin) are thought to be beneficial through a variety of regulatory mechanisms, including cell survival, neurogenesis, improvement of neuroinflammation, protein degradation, and oxidative stress regulation. To date, only a few myokines have been investigated for their effects. Therefore, due to the possibility of these compounds to control many aspects of the disease, future studies are needed to better explore the role of myokines in ALS. In accord, in SOD1-G93A and MLC/SOD1-G93A mice, we previously found a decreased expression of irisin. This decrease may disturb muscle-nerve connection, suggesting its possible role in therapy. Thus, we focus our attention on irisin with the aim to restore muscle-nerve crosstalk and inflammatory response, and promising studies are in progress. Irisin is a recently discovered hormone released from skeletal muscle during exercise and is also considered as a crucial therapeutic agent in a wide variety of metabolic diseases [115]. Since irisin efficiently triggers metabolism and mitochondrial biogenesis in myocytes, it gained attention in the field of neuromuscular diseases. Irisin was found to contrast denervation and oxidative stress [27,116], suggesting a beneficial role in ALS. Recent studies showed that irisin expression increased in patients affected by metabolic disorders and cancer cachexia [117]. Moreover, it was found increased in blood of ALS patients with great disability [118]. Conversely, expression of irisin was reduced in patients with type 2 diabetes and non-alcoholic fatty liver disease. Most recent studies have demonstrated that serum irisin concentration was reduced in patients with breast cancer and exerts inhibitory effect on malignant breast cancer cells [117]. In this regard, further study of these pathways may be useful to assess the role of this myokine in
a situation of inactivity such as ALS. Preclinical studies are required to examine the efficacy of these compounds before proposing clinical trials. These modulators can be useful also as a supportive therapy. In conclusion, drugs targeting skeletal muscle can be a new field of interest in ALS therapy and to ameliorate respiratory function.

Table 2. Preclinical studies in ALS models. In vivo and in vitro effects of different pharmacological compounds at pre-synaptic and post-synaptic level.

| Administered Compound | Animal Model/In Vitro Model | Effects on Pre-Synaptic Target (MN, NMJ) | Effects on Post-Synaptic Target (Skeletal Muscle) | Effects on Survival | References |
|-----------------------|-----------------------------|----------------------------------------|--------------------------------------------------|---------------------|------------|
| GDNF                  | SOD1-G93A rats              | Amelioration of denervation             | Lower rate of motor dysfunction                   | Increase of survival | [81]       |
|                       | SOD1-G93A mouse model       | Reduced rate of denervation and increased survival of spinal MNs | Improvement of locomotor performance              | Increased life span by 17 days | [82]       |
| VEGF                  | SOD1-G93A mouse model       | Protection of spinal and brainstem motor neurons, increase of vascularization | Amelioration of locomotor performance              | Increase of life expectancy | [84]       |
| IGF1                  | SOD1-G93A mouse model       | NMJ stabilization, reduced inflammation in the spinal cord, enhanced motor neuronal survival | Reduction of muscle atrophy                       | Increase of life expectancy | [14,87]    |
| metformin             | C9orf72 ALS/FTD mouse       | Improvement of neurological phenotype   | -                                                 | -                   | [93]       |
| trimetazidine         | SOD1-G93A mouse model       | Prevention of NMJ dismantlement, attenuation of motor neuron loss and functional decline, reduction of neuroinflammation | Stimulation of energy metabolism, myogenesis, muscle strength and oxidative metabolism | Extension of survival | [94]       |
| ranolazine            | SOD1-G93A mouse model       | -                                      | marked increase in muscle strength and function   | -                   | [98]       |
| niclosamide           | ALS-FUS mice                | Amelioration of axonal impairment       | beneficial effects on muscle atrophy, increase of muscle regeneration and reduction of fibrosis. | -                   | [99]       |
| dasatinib             | SOD1-G93A mouse model       | Improvement of the innervation status   | Partial recovery of motor dysfunction             | Improvement of survival | [100]      |
| mexiletine            | SOD1-G93A cultured cells    | Prevention of MN death                  | -                                                 | -                   | [104]      |
| retigabine            | In vitro model of ALS       | Reduction of MN excitability and death  | -                                                 | -                   | [105]      |
| PKC inhibitor         | In vitro model of ALS (SOD1-G93A) | Prevention of NMJ dismantlement       | Amelioration of muscle function                   | -                   | [25]       |
| acetazolamide         | In vitro model of ALS (SOD1-G93A) | -                                    | Amelioration of muscle function                   | -                   | [22]       |

5. Conclusions

New evidences have highlighted the role of skeletal muscle in ALS etiopathogenesis. Indeed, NMJ dismantlement and muscle atrophy are early events in ALS and precede denervation, suggesting skeletal muscle as an important player in this pathology. Here, we have shown different drugs employed in preclinical and clinical studies that have targeted
skeletal muscle with the aim to evidence possible therapeutic interventions that can improve its function and protect motor neurons. For instance, skeletal muscle ion channels are important for its function and can be determinant of ALS pathogenesis and target of drugs. We found involvement of the skeletal muscle chloride channel, CIC-1, a channel already observed to be involved in muscle channelopathies [119–123] and other neurodegenerative disorders [124]. This channel is affected during muscle atrophy [125,126], modified by oxidative stress [127] and growth factors changes [47,128], and its functional characterization links a reduction of CIC-1 activity to an abnormal sarcolemma hyperexcitability. Thus, skeletal muscle function can be ameliorated by the action of regenerative molecules that are able to restore the expression of pivotal genes and proteins, such as chloride channels. These important pro-myogenic factors can support skeletal muscle by mediating the effect of exercise and by sustaining myogenesis and neurogenesis. They can promote muscle hypertrophy and improve muscle strength, and ameliorate metabolism and energy production [27]. These effects can be of importance to slow down the progression of the disease.

Author Contributions: Conceptualization, N.T., I.C., G.M.C., and S.P.; data curation, N.T., I.C., and G.M.C.; writing—original draft preparation, S.P.; writing—review and editing N.T., I.C., G.M.C., and S.P. All authors have read and agreed to the published version of the manuscript.

Funding: This research received no external funding.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.

References
1. Bonifacino, T.; Rebosio, C.; Provenzano, F.; Toraza, C.; Balbi, M.; Milanese, M.; Raiteri, L.; Usai, C.; Fedele, E.; Bonanno, G. Enhanced Function and Overexpression of Metabotropic Glutamate Receptors 1 and 5 in the Spinal Cord of the SOD1G93A Mouse Model of Amyotrophic Lateral Sclerosis during Disease Progression. Int. J. Mol. Sci. 2019, 20, 4552. [CrossRef] [PubMed]
2. Martineau, É.; Arbour, D.; Vallée, J.; Robitaille, R. Properties of Glial Cell at the Neuromuscular Junction Are Incompatible with Synaptic Repair in the SOD1G37R ALS Mouse Model. J. Neurosci. 2020, 40, 7759–7777. [CrossRef] [PubMed]
3. Boillée, S.; Velde, V.C.; Cleveland, D.W. ALS: A disease of motor neurons and their nonneuronal neighbors. Neuron 2006, 52, 39–59. [CrossRef]
4. Pasinelli, P.; Brown, R.H. Molecular biology of amyotrophic lateral sclerosis: Insights from genetics. Nat. Rev. Neurosci. 2006, 7, 710–723. [CrossRef]
5. Bonifacino, T.; Zerbo, R.A.; Balbi, M.; Toraza, C.; Frumento, G.; Fedele, E.; Bonanno, G.; Milanese, M. Nearly 30 Years of Animal Models to Study Amyotrophic Lateral Sclerosis: A Historical Overview and Future Perspectives. Int. J. Mol. Sci. 2021, 22, 12236. [CrossRef]
6. Musarò, A. Understanding ALS: New therapeutic approaches. FEBS J. 2013, 280, 4315–4322. [CrossRef] [PubMed]
7. Gurney, M.E.; Pu, H.; Chiu, A.Y.; Dal Canto, M.C.; Polchow, C.Y.; Alexander, D.D.; Caliendo, J.; Hentati, A.; Kwon, Y.W.; Deng, H.X.; et al. Motor neuron degeneration in mice that express a human Cu,Zn superoxide dismutase mutation. Science 1994, 264, 1772–1775, Erratum in Science 1995, 269, 149. [CrossRef]
8. Ludolph, A.C.; Bendotti, C.; Blaugrund, E.; Chiò, A.; Greensmith, L.; Loeffler, J.P.; Mead, R.; Niessen, H.G.; Petri, S.; Pradat, P.F.; et al. Guidelines for preclinical animal research in ALS/MND: A consensus meeting. Amyotroph. Lateral Scler. 2010, 11, 38–45. [CrossRef] [PubMed]
9. Cleveland, D.W.; Rothstein, J.D. From Charcot to Lou Gehrig: Deciphering selective motor neuron death in ALS. Nat. Rev. Neurosci. 2001, 2, 806–819. [CrossRef] [PubMed]
10. Cozzolino, M.; Pesaresi, M.G.; Gerbino, V.; Grosskreutz, J.; Carri, M.T. Amyotrophic lateral sclerosis: New insights into underlying molecular mechanisms and opportunities for therapeutic intervention. Antioxid. Redox Signal. 2012, 17, 1277–1330. [CrossRef]
11. Beghi, E.; Chiò, A.; Couratier, P.; Esteban, J.; Hardiman, O.; Logroscino, G.; MillUL, A.; Mitchell, D.; Preux, P.M.; Pupillo, E.; et al. Eurals Consortium. The epidemiology and treatment of ALS: Focus on the heterogeneity of the disease and critical appraisal of therapeutic trials. Amyotroph. Lateral Scler. 2011, 12, 1–10. [CrossRef] [PubMed]
12. Lacomblez, L.; Bensimon, G.; Leigh, P.N.; Guillet, P.; Meininger, V. Dose-ranging study of riluzole in amyotrophic lateral sclerosis. Amyotrophic Lateral Sclerosis/Riluzole Study Group II. Lancet 1996, 347, 1425–1431. [CrossRef]
13. Brooks, B.R.; Pioro, E.P.; Katz, J.; Takahashi, F.; Takei, K.; Zhang, J.; Apple, S. Slowing the loss of physical function in amyotrophic lateral sclerosis with edaravone: Post hoc analysis of ALSFRS-R item scores in pivotal study MCI186–19. *Muscle Nerve* 2021, 65, 180–186. [CrossRef] [PubMed]

14. Dobrowolny, G.; Giacinti, C.; Pelosi, L.; Nicoletti, C.; Winn, N.; Barberi, L.; Molinaro, M.; Rosenthal, N.; Musarò, A. Muscle expression of a local Igf-1 isoform protects motor neurons in an ALS mouse model. *J. Cell Biol.* 2005, 168, 193–199. [CrossRef] [PubMed]

15. Wong, M.; Martin, L.J. Skeletal muscle-restricted expression of human SOD1 causes motor neuron degeneration in transgenic mice. *Hum. Mol. Genet.* 2010, 19, 2284–2302. [CrossRef]

16. Dobrowolny, G.; Bernardini, C.; Martinis, M.; Baranzini, M.; Barba, M.; Musarò, A. Muscle Expression of SOD1(G93A) Modulates microRNA and mRNA Transcription Pattern Associated with the Myelination Process in the Spinal Cord of Transgenic Mice. *Front. Cell Neurosci.* 2015, 9, 463. [CrossRef] [PubMed]

17. Fracchiolla, G.; Laghezza, A.; Piemontese, L.; Tortorella, P.; Mazza, F.; Montanari, R.; Pochetti, G.; Lavecchia, A.; Novellino, E.; Pierno, S.; et al. New 2-aryloxy-3-phenyl-propanoic acids as peroxisome proliferator-activated receptors alpha/gamma dual agonists with improved potency and reduced adverse effects on skeletal muscle function. *J. Med. Chem.* 2009, 52, 6382–6393. [CrossRef]

18. Camerino, G.M.; De Bellis, M.; Conte, E.; Liantonio, A.; Musaraj, K.; Canonne, M.; Fonzino, A.; Giustino, A.; De Luca, A.; Romano, R.; et al. Statin-induced myotoxicity is exacerbated by aging: A biophysical and molecular biology study in rats treated with atorvastatin. *Toxicol. Appl. Pharmacol.* 2016, 306, 36–46. [CrossRef]

19. Desaphy, J.-F.; Gramegna, G.; Altamura, C.; Dinardo, M.M.; Imbri, P.; George, A.L., Jr.; Modoni, A.; Lomonaco, M.; Conte Camerino, D. Functional characterization of CIC-1 mutations from patients affected by recessive myotonia congenita presenting with different clinical phenotypes. *Exp. Neurol.* 2013, 248, 530–540. [CrossRef]

20. Altamura, C.; Mangiatiordi, G.F.; Nicolotti, O.; Sahbani, D.; Farinato, A.; Leonetti, F.; Carratù, M.R.; Conte, D.; Desaphy, J.-F.; Imbri, P. Mapping ligand-binding pockets in CIC-1 channels through an integrated in silico and experimental approach using anthracene-9-carboxylic acid and niflumic acid. *Br. J. Pharmacol.* 2018, 175, 1770–1780. [CrossRef]

21. Desaphy, J.-F.; Farinato, A.; Altamura, C.; De Bellis, M.; Imbri, P.; Tarantino, N.; Caccia, C.; Melloni, R.; Padoani, G.; Vailati, S.; et al. Safinamide potential in nondystrophic myotonias: Inhibition of skeletal muscle voltage-gated sodium channels and skeletal muscle hyperexcitability in vitro and in vivo. *Exp. Neurol.* 2020, 328, 113287. [CrossRef] [PubMed]

22. Camerino, G.M.; Fonzino, A.; Conte, E.; De Bellis, M.; Mele, A.; Liantonio, A.; Tricarico, D.; Tarantino, N.; Dobrowolny, G.; Musarò, A.; et al. Elucidating the Contribution of Skeletal Muscle Ion Channels to Amyotrophic Lateral Sclerosis in search of new therapeutic options. *Sci. Rep.* 2019, 9, 3185. [CrossRef] [PubMed]

23. Pierno, S.; Desaphy, J.F.; Liantonio, A.; De Bellis, M.; Bianco, G.; De Luca, A.; Frigeri, A.; Nicchia, G.P.; Svelto, M.; Lioni, E.; et al. Change of chloride ion channel conductance is an early event of slow-to-fast fibre type transition during unloading-induced muscle disuse. *Brain* 2002, 125, 1510–1521. [CrossRef] [PubMed]

24. De Luca, A.; Pierno, S.; Conte Camerino, D. Electrical properties of diaphragm and EDL muscles during the life of dystrophic mice. *Am. J. Physiol.* 1997, 272, C33–C340. [CrossRef] [PubMed]

25. Dobrowolny, G.; Martini, M.; Sciccitano, B.M.; Romanello, V.; Boncompagni, S.; Nicoletti, C.; Pietrangelo, L.; De Panfilis, S.; Catizone, A.; Bouché, M.; et al. Muscle expression of SOD1(G93A) triggers the dismantlement of neuromuscular junction via PKC-Theta. *Antioxid. Redox Signal.* 2018, 28, 1105–1119. [CrossRef]

26. Lanuza, M.A.; Just-Borràs, L.; Hurtado, E.; Cillerós-Mañé, V.; Tomàs, M.; García, N.; Tomàs, J.; et al. The impact of kinases in Amyotrophic Lateral Sclerosis at the neuromuscular synapse: Insights into BDNF/TrkB and PKC signaling. *J. Cells* 2019, 8, 1578. [CrossRef]

27. Reza, M.M.; Subramaniyam, N.; Sim, C.M.; Ge, X.; Sathiakumar, D.; McFarlane, C.; Sharma, M.; Kambadur, R. Irisin is a pro-myogenic factor that induces skeletal muscle hypertrophy and rescues denervation-induced atrophy. *Nat. Commun.* 2017, 8, 1104. [CrossRef]

28. Kablar, B.; Rudnicki, M.A. Development in the absence of skeletal muscle results in the sequential ablation of motor neurons from the spinal cord to the brain. *Dev. Biol.* 1999, 208, 103–9. [CrossRef] [PubMed]

29. Lino, M.M.; Schneider, C.; Caroni, P. Accumulation of SOD1 mutants in postnatal motoneurons does not cause motoneuron pathology or motoneuron disease. *J. Neurosci.* 2002, 22, 4825–4832. [CrossRef]

30. Pramatarova, A.; Laganère, J.; Roussel, J.; Brichebois, K.; Rouleau, G.A. Neuron-specific expression of mutant superoxide dismutase 1 in transgenic mice does not lead to motor impairment. *J. Neurosci.* 2001, 21, 3369–3374. [CrossRef]

31. De Bellis, M.; Carbonara, R.; Roussel, J.; Farinato, A.; Massari, A.; Pierno, S.; Muraglia, M.; Corbo, F.; Franchini, C.; Carratù, M.R.; et al. Increased sodium channel use-dependent inhibition by a new potent analogue of tocainide greatly enhances in vivo antimitotic activity. *Neuropharmacology* 2017, 113, 206–216. [CrossRef]
Ly, C.V.; Miller, T.M. Emerging antisense oligonucleotide and viral therapies for amyotrophic lateral sclerosis. Curr. Opin. Neurol. 2018, 31, 648–654. [CrossRef]

Biferi, M.G.; Cohen-Tannoudji, M.; Cappelletto, A.; Giroux, B.; Roda, M.; Astord, S.; Marais, T.; Bos, C.; Voit, T.; Ferry, A.; et al. A New AAV10-U7-Mediated Gene Therapy Prolongs Survival and Restores Function in an ALS Mouse Model. Mol. Ther. 2017, 25, 2038–2052. [CrossRef]

Jiang, J.; Zhu, Q.; Gendron, T.F.; Saberi, S.; McAlonis-Downes, M.; Seelam, A.; Stauffer, J.E.; Jafar-Nejad, P.; Drenner, K.; Schulte, D.; et al. Gain of toxicity from ALS/FTD-linked repeat expansions in C9ORF72 is alleviated by antisense oligonucleotides targeting GGGGCC-containing RNAs. Neuron 2016, 90, 535–550. [CrossRef]

Miller, T.; Cudkowicz, M.; Shaw, P.F.; Andersen, P.M.; Assassi, N.; Bucelli, R.C.; Genge, A.; Glass, J.; Ladha, S.; Ludolph, A.L.; et al. Phase 1–2 Trial of Antisense Oligonucleotide Tofersen for SOD1 ALS. N. Engl. J. Med. 2020, 383, 109–119. [CrossRef]

Lange, D.J.; Shahbazi, M.; Silani, V.; Ludolph, A.C.; Weishaupt, J.H.; Ajroud-Driss, S.; Fields, K.G.; Remanana, R.; Appel, S.H.; Morelli, C.; et al. Pyrimethamine significantly lowers cerebrospinal fluid Cu/Zn superoxide dismutase in amyotrophic lateral sclerosis patients with SOD1 mutations. Ann. Neurol. 2017, 81, 837–848. [CrossRef] [PubMed]

Mazzini, L.; Mareschi, K.; Ferrero, I.; Vassallo, E.; Oliveri, G.; Nasuelli, N.; Oggiioni, G.D.; Testa, L.; Fagioli, F. Stem cell treatment in amyotrophic lateral sclerosis. J. Neurosci. 2008, 28, 78–83. [CrossRef] [PubMed]

Keeler, A.M.; Ziegler, M.; Semple, C.; Pucci, L.; Veinbachs, A.; Brown, R.H., Jr.; Mueller, C.; El Mallah, M.K. Intralingual and Intrapleural AAV Gene Therapy Prolongs Survival in a SOD1 ALS Mouse Model. Mol. Ther. Methods Clin. Dev. 2019, 17, 246–257. [CrossRef] [PubMed]

Lind, L.A.; Andel, E.M.; McCall, A.L.; Dhindsa, J.S.; Johnson, K.A.; Stricklin, O.E.; Mueller, C.; El Malah, M.K.; Lever, T.E.; Nichols, N.L. Intralingual Administration of AAVrh10-mirSOD1 Improves Respiratory But Not Slowing Function in a Superoxide Dismutase-1 Mouse Model of Amyotrophic Lateral Sclerosis. Hum. Gene Ther. 2020, 31, 828–838. [CrossRef]

Mueller, C.; Berry, J.D.; McKenna-Yasek, D.M.; Gernoux, G.; Owegi, M.A.; Pothier, L.M.; Douthwright, C.L.; Gelevski, D.; Luppino, S.D.; Blackwood, M.; et al. SOD1 Suppression with Adeno-Associated Virus and MicroRNA in Familial ALS. N. Engl. J. Med. 2020, 383, 151–158. [CrossRef] [PubMed]

Devos, D.; Moreau, C.; Kyheng, M.; Garçon, G.; Rolland, A.S.; Blasco, H.; Gelé, P.; Timothée Lenglet, T.; Veyrat-Durebex, C.; Corcia, P.; et al. A ferroptosis-based panel of prognostic biomarkers for Amyotrophic Lateral Sclerosis. Sci. Rep. 2019, 9, 2918. [CrossRef]

Kaufmann, P.; Thompson, J.L., Jr.; Levy, G.; Buchsbaum, R.; Shefner, J.; Krivickas, L.; Katz, J.; Rollins, Y.; Barohn, R.J.; Jackson, C.E.; et al. Phase II trial of CoQ10 for ALS finds insufficient evidence to justify phase III. Ann. Neurol. 2009, 66, 235–244. [CrossRef]

Saccà, F.; Quarantelli, M.; Rinaldi, C.; Tucci, T.; Piro, R.; Perrotta, G.; Carotenuto, B.; Marsili, A.; Palma, V.; De Michele, G.; et al. A randomized controlled clinical trial of growth hormone in amyotrophic lateral sclerosis: Clinical, neuroimaging, and hormonal results. J. Neurol. 2012, 259, 132–138. [CrossRef] [PubMed]

Andrews, J.A.; Cudkowicz, M.E.; Hardiman, O.; Meng, L.; Bian, A.; Lee, J.; Wolff, A.A.; Malik, F.I.; Shefner, J.M. VITALITY-ALS, a phase III trial of tirasemtiv, a fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: Study design and baseline characteristics. Amyotroph. Lateral Scler. Frontotemporal. Degener. 2018, 19, 259–266. Erratum in Amyotroph. Lateral Scler. Frontotemporal. Degener. 2018, 19, 321. [CrossRef]

Shefner, J.M.; Andrews, J.A.; Genge, A.; Jackson, C.; Lechtzin, N.; Miller, T.M.; Cockroft, B.M.; Meng, L.; Wie, J.; Wolff, A.A.; et al. A Phase 2, Double-Blind, Randomized, Dose-Ranging Trial Of Reldesemtiv In Patients With ALS. Amyotroph. Lateral Scler. Frontotemporal. Degener. 2021, 22, 287–299. [CrossRef]

Wainger, B.J.; Macklin, E.A.; Vucic, S.; Mclduff, C.E.; Paganoni, S.; Maragakis, N.J.; Bedlack, R.; Goyal, N.A.; Rutkove, S.B.; Lange, D.J.; et al. Effect of Ezogabine on Cortical and Spinal Motor Neuron Excitability in Amyotrophic Lateral Sclerosis: A Randomized Clinical Trial. JAMA Neurol. 2021, 78, 186–196. [CrossRef] [PubMed]

Oskarsson, B.; Moore, D.; Mozaffar, T.; Ravits, J.; Wiedau-Pazos, M.; Parziale, N.; Joyce, N.C.; Mandeville, R.; Goyal, N.; Cudkowicz, M.E.; et al. Mexilinetine for muscle cramps in amyotrophic lateral sclerosis: A randomized, double-blind crossover trial. Muscle Nerve 2018, 58, 42–48. [CrossRef]

Cudkowicz, M.; Genge, A.; Maragakis, N.; Petri, S.; van den Berg, L.; Aho, V.V.; Sarapohja, T.; Kuooppamäki, M.; Garratt, C.; Al-Chalabi, A.; et al. Safety and efficacy of oral levosimendan in people with amyotrophic lateral sclerosis (the REFALS study): A randomised, double-blind, placebo-controlled phase 3 trial. Lancet Neurol. 2021, 20, 821–831. [CrossRef]

Mandrioli, J.; Crippa, V.; Cereda, C.; Bonetto, V.; Zucchi, E.; Gessani, A.; Ceroni, M.; Chio, A.; D’Amico, R.; Monsurro, M.R.; et al. Proteostasis and ALS: Protocol for a phase II, randomised, double-blind, placebo-controlled, multicentric clinical trial for colchicine in ALS (CO-ALS). BMJ Open 2019, 9, e028486. [CrossRef]

De la Rubia, J.E.; Drehmer, E.; Platero, J.I.; Benlloch, M.; Capilllure-Llopis, J.; Villaron-Casales, C.; de Bernardo, N.; Alarcòn, J.; Fuente, C.; Carrera, S.; et al. Efficacy and tolerability of EHS01 for amyotrophic lateral sclerosis: A randomized, double-blind, placebo-controlled human pilot study. Amyotroph. Lateral Scler. Frontotemporal. Degener. 2019, 20, 115–122. [CrossRef] [PubMed]

Meiningier, V.; Genge, A.; van den Berg, L.H.; Robberecht, W.; Ludolph, A.; Chio, A.; Kim, S.H.; Leigh, P.N.; Kiernan, M.C.; Shefner, J.M.; et al. Safety and efficacy of ozanezumab in patients with amyotrophic lateral sclerosis: A randomised, double-blind, placebo-controlled, phase 2 trial. Lancet Neurol. 2017, 16, 208–216. [CrossRef] [PubMed]

Arrat, H.; Lukas, T.J.; Siddique, T. ACTH (Acthar Gel) Reduces Toxic SOD1 Protein Linked to Amyotrophic Lateral Sclerosis in Transgenic Mice: A Novel Observation. PLoS ONE 2015, 10, e0125638. [CrossRef] [PubMed]
Cells 2022, 11, 415

78. Drory, V.E.; Goltsman, E.; Reznik, J.G.; Mosek, A.; Korczyn, A.D. The value of muscle exercise in patients with amyotrophic lateral sclerosis. J. Neurol. Sci. 2001, 191, 133–137. [CrossRef]

79. Bello-Haas, V.D.; Florence, J.M.; Kloos, A.D.; Scheirbecker, J.; Lopate, G.; Hayes, S.M.; Pioro, E.P.; Mitsumoto, H. A randomized controlled trial of resistance exercise in individuals with ALS. Neurology 2007, 68, 2003–2007. [CrossRef] [PubMed]

80. Manzano, R.; Toivonen, J.M.; Moreno-Martinez, L.; de la Torre, M.; Moreno-Garcia, L.; López-Royo, T.; Molina, N.; Zaragoza, P.; Calvo, A.C.; Osta, R. What skeletal muscle has to say in amyotrophic lateral sclerosis: Implications for therapy. Br. J. Pharmacol. 2021, 178, 1279–1297. [CrossRef]

81. Suzuki, M.; McHugh, J.; Tork, C.; Shelley, B.; Hayes, A.; Bellantuono, I.; Aebrischer, P.; Svendsen, C.N. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol. Ther. 2008, 16, 2002–2010. [CrossRef]

82. Li, W.; Brakefield, D.; Pan, Y.; Hunter, D.; Myckatyn, T.M.; Parsadanian, A. Muscle-derived but not centrally derived transgene GDNF is neuroprotective in G93A-SOD1 mouse model of ALS. Exp. Neurol. 2007, 203, 457–471. [CrossRef] [PubMed]

83. Shim, J.W.; Madsen, J.R. VEGF signaling in neurological disorders. Int. J. Mol. Sci. 2018, 19, 275. [CrossRef] [PubMed]

84. Azzouz, M.; Ralph, G.S.; Storkebaum, E.; Walmsley, L.E.; Mitrophanous, K.A.; Kingsman, S.M.; Carmellet, P.; Mazarakis, N.D. VEGF delivery with retrogradely transported lentivector prolongs survival in a mouse ALS model. Nature 2004, 429, 413–417. [CrossRef] [PubMed]

85. Ngo, S.T.; Cole, R.N.; Sunn, N.; Phillips, W.D.; Noakes, P.G. Neuregulin-1 potentiates agrin-induced acetylcholine receptor clustering through muscle-specific kinase: Phosphorylation. J. Cell Sci. 2012, 125, 1531–1543. [CrossRef] [PubMed]

86. Modél-Caballero, G.; Herrando-Grabulosa, M.; García-Lareu, B.; Solanes, N.; Verdés, S.; Osta, R.; Frances-Quijorna, L.; López-Vales, R.; Calvo, A.C.; Bosch, A.; et al. Gene therapy for overexpressing Neuregulin 1 type I in skeletal muscles promotes functional improvement in the SOD1G93A ALS mouse. Neurobiol. Dis. 2020, 137, 104793. [CrossRef] [PubMed]

87. Zuccaro, E.; Piol, D.; Basso, M.; Pennuto, M. Motor Neuron Diseases and Neuroprotective Peptides: A Closer Look to Neurons. Front. Aging Neurosci. 2021, 13, 723871. [CrossRef]

88. Beal, M.F. Neuroprotective effects of creatine. Amino Acids 2011, 40, 1305–1313. [CrossRef]

89. Cappello, V.; Vezzoli, E.; Righi, M.; Fossati, M.; Mariotti, R.; Crespi, A.; Patruno, M.; Bentivoglio, M.; Pietrini, G.; Francolini, M. Analysis of neuromuscular junctions and effects of anabolic steroid administration in the SOD1G93A mouse model of ALS. Mol. Cell Neurosci. 2012, 51, 12–21. [CrossRef] [PubMed]

90. Vergouts, M.; Marinangelo, C.; Ingelbrecht, C.; Genard, G.; Schakman, O.; Sternotte, A.; Calas, A.G.; Hermanas, E. Early ALS-type gait abnormalities in AMPK-dependent protein kinase-deficient mice suggest a role for this metabolic sensor in early stages of the disease. Metab. Brain Dis. 2015, 30, 1369–1377. [CrossRef]

91. Kjøbsted, R.; Hingst, J.R.; Fentz, J.; Foretz, M.; Sanz, M.N.; Pehmøller, C.; Shum, M.; Mounier, R.; Treebak, J.T.; et al. AMPK in skeletal muscle function and metabolism. FASEB J. 2018, 32, 1741–1777. [CrossRef] [PubMed]

92. Mantuano, P.; Sanarica, F.; Conte, E.; Verges-Royo, T.; Molina, N.; Molina, N.; Zuccaro, E.; Piol, D.; Basso, M.; Pennuto, M.; Meda, P.; Mazzarini, N. Direct muscle delivery of GDNF with human mesenchymal stem cells improves motor neuron survival and function in a rat model of familial ALS. Mol. Ther. 2008, 16, 2002–2010. [CrossRef]

93. Milani, M.; Mammarella, E.; Rossi, S.; Miele, C.; Lattante, S.; Sabatelli, M.; Cozzolino, M.; D’Ambrosi, N.; Apolloni, S. Targeting S100A4 with niclosamide attenuates inflammatory and profibrotic pathways in models of amyotrophic lateral sclerosis. J. Neuroinflammation 2021, 18, 132. [CrossRef]

94. Katsumata, R.; Ishigaki, S.; Katsuno, M.; Kawai, K.; Sone, J.; Huang, Z.; Adachi, H.; Tanaka, F.; Urano, F.; Sobue, G. e-Abl inhibition delays motor neuron degeneration in the G93A mouse, an animal model of amyotrophic lateral sclerosis. PLoS ONE 2012, 7, e46185. [CrossRef]

95. Kjøbsted, R.; Hingst, J.R.; Fentz, J.; Foretz, M.; Sanz, M.N.; Pehmøller, C.; Shum, M.; Mounier, R.; Treebak, J.T.; et al. AMPK in skeletal muscle function and metabolism. FASEB J. 2018, 32, 1741–1777. [CrossRef] [PubMed]
101. Mantuano, P.; Boccanegra, B.; Conte, E.; De Bellis, M.; Cirmi, S.; Sanarica, F.; Cappellari, O.; Arduino, I.; Cutrignelli, A.; Lopedota, A.A.; et al. β-Dystroglycan Restoration and Pathology Progression in the Dystrophic mdx Mouse: Outcome and Implication of a Clinically Oriented Study with a Novel Oral Dasatinib Formulation. *Biomolecules* 2021, 11, 1742. [CrossRef] [PubMed]

102. Vucec, S.; Nicholson, G.A.; Kiernan, M.C. Cortical hyperexcitability may precede the onset of familial amyotrophic lateral sclerosis. *Brain* 2008, 131, 1540–1550. [CrossRef] [PubMed]

103. Roselli, E.; Caroni, P. Modeling neuronal vulnerability in ALS. *Neuron* 2014, 83, 758–760. [CrossRef] [PubMed]

104. Fritz, E.; Izaurea, P.; Weiss, A.; Mir, F.R.; Rojas, P.; Gonzalez, D.; Rojas, F.; Brown, R.H., Jr.; Madrid, R.; van Zundert, B. Mutant SOD1-expressing astrocytes release toxic factors that trigger motoneuron death by inducing hyperexcitability. *J. Neurophysiol.* 2013, 109, 2803–2814. [CrossRef]

105. Ghezzi, F.; Morni, L.; Nistri, A. Functional up-regulation of the M-current by retigabine contrasts hyperexcitability and excitotoxicity on rat hypoglossal motoneurons. *J. Physiol.* 2018, 596, 2611–2629. [CrossRef]

106. Eguchi, H.; Tsujino, A.; Kaibara, M.; Hayashi, H.; Shirabe, S.; Taniyama, K.; Eguchi, K. Acetazolamide acts directly on the human skeletal muscle chloride channel. *Muscle Nerve* 2006, 34, 292–297. [CrossRef]

107. Altmara, C.; Lucchiar, S.; Sabbani, D.; Ulzi, G.; Comi, G.P.; D’Ambrosio, P.; Petillo, R.; Politano, L.; Vercelli, L.; Mongini, T.; et al. The analysis of myotonia congenita mutations discloses functional clusters of amino acids within CBS2 domain and C-terminal peptide of CIC-1 channel. *Hum. Mutat.* 2018, 39, 1273–1283. [CrossRef]

108. Altmara, C.; Fonzino, A.; Tarantinio, N.; Conte, E.; Liantonio, A.; Imbrici, P.; Carratu, M.R.; Pierno, S.; Desaphy, J.-F. Increased sarcocomla chloride conductance as one of the mechanisms of action of carboanhydrase inhibitors in muscle excitability disorders. *Exp. Neurol.* 2021, 342, 113758. [CrossRef]

109. Cozzoli, A.; Liantonio, A.; Conte, E.; Cannone, M.; Massari, A.M.; Giustino, A.; Scaramuzzi, A.; Pierno, S.; Mantuano, P.; Capogrosso, R.F.; et al. Angiotensin II modulates mouse skeletal muscle resting conductance to chloride and potassium ions and calcium homeostasis via the AT1 receptor and NADPH oxidase. *Am. J. Physiol. Cell Physiol.* 2014, 307, C634–C647. [CrossRef]

110. Camerino, G.M.; Bouché, M.; De Bills, M.; Cannone, M.; Liantonio, A.; Musaraj, K.; Romano, R.; Smeriglio, P.; Madaro, L.; Giustino, A.; et al. Protein kinase C theta (PKCθ) modulates the CIC-1 chloride channel activity and skeletal muscle phenotype: A biophysical and gene expression study in mouse models lacking the PKCθ. *Pflugers Arch.* 2014, 466, 2215–2228. [CrossRef]

111. Gillon, A.; Nielsen, K.; Steel, C.; Cornwall, J.; Sheard, P. Exercise attenuates age-associated changes in motoneuron number, nucleocytoplasmic transport proteins and neuromuscular health. *GeroScience* 2018, 40, 177–192. [CrossRef] [PubMed]

112. Sailani, M.R.; Halling, J.F.; Møller, H.D.; Lee, H.; Plomgaard, P.; Pilegaard, H.; Snyder, M.P.; Regenberg, B. Lifelong physical activity is associated with promoter hypomethylation of genes involved in metabolism, myogenesis, contractile properties and oxidative stress resistance in aged human skeletal muscle. *Sci. Rep.* 2019, 9, 3272. [CrossRef] [PubMed]

113. Ruegsaeger, G.N.; Booth, F.W. Health benefits of exercise. *Cold Spring Harb. Perspect. Med.* 2018, 8, a029694. [CrossRef] [PubMed]

114. Cieminski, K.; Flis, D.J.; Dzik, K.; Kaczor, J.J.; Czyrko, E.; Halon-Golabek, M.; Wieckowski, M.R.; Antosiewicz, J.; Ziolkowski, M.; et al. Multidisciplinary study of a new ClC-1 mutation causing myotonia congenita: A paradigm to understand and treat ion channelopathies. *FASEB J.* 2018, 32, 593–599. [CrossRef]

115. Boström, P.; Wu, J.; Jedyrchowsky, M.P.; Korde, A.; Ye, L.; Lo, J.C.; Rasbach, K.A.; Boström, E.A.; Choi, J.H.; Long, J.Z.; et al. A PGC1-α-dependent myokine that drives brown-fat-like development of white fat and thermogenesis. *Nature 2012, 481, 463–468. [CrossRef] [PubMed]

116. Askari, H.; Rajani, S.F.; Poorebrahim, M.; Hagh-Aminian, H.; Raisi-Abbodlali, E.; Abbodlali, M. A glance at the therapeutic potential of irisin against diseases involving inflammation, oxidative stress, and apoptosis: An introductory review. *Pharmacol. Res.* 2018, 129, 44–55. [CrossRef]

117. Sumsuzzman, D.M.; Jin, Y.; Choi, J.; Yu, J.H.; Lee, T.H.; Hong, Y. Pathophysiological role of endogenous irisin against tumorigenesis and metastasis: Is it a potential biomarker and therapeutic? *Tumour. Biol.* 2019, 41, 1010423819892790. [CrossRef]

118. Lunetta, C.; Lizio, A.; Tremolizzo, L.; Ruscica, M.; Macchi, C.; Riva, N.; Weydt, P.; Corradi, E.; Magni, P.; Sansone, V. Serum irisin is upregulated in patients affected by amyotrophic lateral sclerosis and correlates with functional and metabolic status. *J. Neurol.* 2018, 265, 3001–3008. [CrossRef]

119. Cannon, S.C. Channelopathies of skeletal muscle excitability. *Compr. Physiol.* 2015, 5, 761–790.

120. Imbrici, P.; Maggi, L.; Mangiardi, G.F.; Dinardo, M.M.; Altmara, C.; Brugnoni, R.; Alberga, D.; Pinter, G.L.; Ricci, G.; Siciliano, G.; et al. CIC-1 mutations in myotonia congenita patients: Insights into molecular gating mechanisms and genotype-phenotype correlation. *J. Physiol.* 2015, 593, 4181–4199. [CrossRef]

121. Imbrici, P.; Altmara, C.; Camerino, G.M.; Mangiardi, G.F.; Conte, E.; Maggi, L.; Brugnoni, R.; Musaraj, K.; Caloiero, R.; Alberga, D.; et al. Multidisciplinary study of a new CIC-1 mutation causing myotonia congenita: A paradigm to understand and treat ion channelopathies. *FASB E* 2016, 30, 3285–3295. [CrossRef] [PubMed]

122. Altmara, C.; Desaphy, J.-F.; Conte, D.; De Luca, A.; Imbrici, P. Skeletal muscle CIC-1 chloride channels in health and diseases. *Pflugers Arch.* 2020, 472, 961–975. [CrossRef]

123. Desaphy, J.-F.; Altmara, C.; Vicart, S.; Fontaine, B. Targeted Therapies for Skeletal Muscle Ion Channelopathies: Systematic Review and Steps Towards Precision Medicine. *J. Neuromuscul. Dis.* 2021, 8, 357–381. [CrossRef]

124. Waters, C.W.; Varuzhanyan, G.; Talmadge, R.J.; Voss, A.A. Huntington disease skeletal muscle is hyperexcitable owing to chloride and potassium channel dysfunction. *Proc. Natl. Acad. Sci. USA* 2013, 110, 9160–9165. [CrossRef] [PubMed]
125. Camerino, G.M.; Musumeci, O.; Conte, E.; Musaraj, K.; Fonzino, A.; Barca, E.; Marino, M.; Rodolico, C.; Tricarico, D.; Camerino, C.; et al. Risk of Myopathy in Patients in Therapy with Statins: Identification of Biological Markers in a Pilot Study. *Front. Pharmacol.* 2017, 8, 500. [CrossRef]

126. Mantuano, P.; Bocanegra, B.; Bianchini, G.; Conte, E.; De Bellis, M.; Sanarica, F.; Camerino, G.M.; Pierno, S.; Cappellari, O.; Allegretti, M.; et al. BCAAs and Di-Alanine supplementation in the prevention of skeletal muscle atrophy: Preclinical evaluation in a murine model of hind limb unloading. *Pharmacol. Res.* 2021, 171, 105798. [CrossRef]

127. Desaphy, J.-F.; Pierno, S.; Liantonio, A.; Giannuzzi, V.; Digennaro, C.; Dinardo, M.M.; Camerino, G.M.; Ricciuti, P.; Brocca, L.; Pellegrino, M.A.; et al. Antioxidant treatment of hindlimb-unloaded mouse counteracts fiber type transition but not atrophy of disused muscles. *Pharmacol. Res.* 2010, 61, 553–563. [CrossRef]

128. Pierno, S.; De Luca, A.; Desaphy, J.-F.; Fraysse, B.; Liantonio, A.; Didonna, M.P.; Lograno, M.; Cocchi, D.; Smith, R.G.; Camerino, D.C. Growth hormone secretagogues modulate the electrical and contractile properties of rat skeletal muscle through a ghrelin-specific receptor. *Br. J. Pharmacol.* 2003, 139, 575–584. [CrossRef]